Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab

BACKGROUND: To assess the effect of switching patients previously incompletely treated with ranibizumab (RBZ) to aflibercept (AFL) using a pro re nata (PRN) treatment strategy in neovascular age-related macular degeneration (nvAMD). METHODS: A retrospective case series was conducted on patients who...

Descripción completa

Detalles Bibliográficos
Autores principales: Elwes, Flora, Borooah, Shyamanga, Aspinall, Peter, Sim, Peng Yong, Loo, Cheng Yi, Armbrecht, Ana-Maria, Dhillon, Baljean, Cackett, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789603/
https://www.ncbi.nlm.nih.gov/pubmed/29378528
http://dx.doi.org/10.1186/s12886-018-0688-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789603/
https://www.ncbi.nlm.nih.gov/pubmed/29378528
http://dx.doi.org/10.1186/s12886-018-0688-3

Ejemplares similares